A reconstituted high density lipoprotein containing the V156E mutant of apolipoprotein A-I exhibits anti-atherosclerotic activity in apo-E deficient mice

Journal of Atherosclerosis and Thrombosis

Volumn 16, Issue 3, 2009, Pages 217-229

  Cho, Kyung Hyun ^a  

^a Yeungnam University   (South Korea)

Author keywords

Antioxidant; Apolipoprotein A I; Atherosclerosis; HDL therapy; V156E

Indexed keywords

APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; LIPID HYDROPEROXIDE; OLEOYLPALMITOYLLECITHIN; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; ENZYME ACTIVITY; FEASIBILITY STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; JAPAN; MACROPHAGE; MOUSE; NONHUMAN; OXIDATION; POINT MUTATION; WILD TYPE;

EID: 70350247529     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.509     Document Type: Article

References (40)

1. Ansell BJ, Watson KE, Fogelman AM, Navab M, Fonarow GC: High density lipoprotein function recent advances. J Am Coll Cardiol, 2005; 46:1792-1798
2. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM: Antiinflammatory properties of HDL. Circ Res, 2004; 95:764-772
3. Alam K, Meidell RS, Spady DK: Effect of up-regulating individual steps in the reverse choleterol transport pathway on reverse cholesterol transport in normolipidemic mice. J Biol Chem, 2001; 276:15641-15649
4. Miyazaki A, Sakuma S, Morikawa W, Takiue T, Miake F, Terano T, Sakai M, Hakamata H, Sakamoto Y, Naito M, Ruan Y, Takahashi K, Ohta T, Horiuchi S: Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol, 1995; 15:1882-1888
5. Nanjee MN, Doran JE, Lerch PG, Miller NE: Acute effects of intravenous infusion of ApoA1/phosphatidylcholine discs on plasma lipoproteins in humans. Arterioscler Thromb Vasc Biol, 1999; 19:979-989
6. Nanjee MN, Cooke CJ, Garvin R, Semeria F, Lewis G, Olszewski WL, Miller NE: Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J Lipid Res, 2001; 42:1586-1593
7. Newton RS, Krause BR: HDL therapy for the acute treatment of atherosclerosis. Atherosclerosis Suppl, 2002; 3:31-38
8. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Datta G, Garber D, Fogelman AM: Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal. Curr Opin Lipidol, 2004; 15:645-649
9. Shah PK, Nilsson J, Kaul S, Fishbein MC, Ageland H, Hamsten A, Johansson J, Karpe F, Cercek B: Effects of recombinant apolipoprotein A-I milano on aortic atherosclerosis in apolipoprotein-E-deficient mice. Circulation, 1998; 97:780-785
10. Chiesa G, Monteggia E, Marchesi M, Lorenzon P, Laucello M, Lorusso V, Di Mario C, Karvouni E, Newton RS, Bisgaier CL, Franceschini G, Sirtori CR: Recombinant apolipoprotein A-I milano infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ Res, 2002; 90:974-980
11. Kaul S, Rukshin V, Santos R, Azarbal B, Bisgaier CL, Johansson J, Tsang VT, Chyu KY, Cercek B, Mirocha J, Shah PK: Intramural delivery of recombinant apolipoprotein A-I milano/phospholipid complex (ETC-216) inhibits in-stent stenosis in porcine coronary arteries. Circulation, 2003; 107:2551-2554
12. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R: Effect of recombinant apoA-I milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. J Am Med Assoc, 2003; 290:2292-2300
13. Nicholls SJ, Tuzcu EM, Sipahi I, Schoenhagen P, Crowe T, Kapadia S, Nissen SE: Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano. J Am Coll Cardiol, 2006; 47:992-997
14. Cho KH, Jonas A: A key point mutation (V156E) affects the structure and functions of human apolipoprotein A-I. J Biol Chem, 2000; 275:26821-26827
15. Cho KH, Durbin DM, Jonas A: Role of individual amino acids of apolipoprotein A-I in the activation of lecithin: cholesterol acyltransferase and in HDL rearrangements. J Lipid Res, 2001; 42:379-389
16. Huang W, Sasaki J, Matsunaga A, Nanimatsu H, Moriyama K, Han H, Kugi M, Koga T, Yamaguchi K, Arakawa K: A novel homozygous missense mutation in the apoA-I gene with apoA-I deficiency. Arterioscler. Thromb Vasc Biol, 1998; 18:389-396
17. Han JM, Jeong TS, Lee WS, Choi I, Cho KH: Structural and functional properties of V156K and A158E mutants of apolipoprotein A-I in the lipid-free and lipid-bound states. J Lipid Res, 2005; 46:589-596
18. Ajees AA, Anantharamaiah GM, Mishra VK, Hussain MM, Murthy HM: Crystal structure of human apolipoprotein A-I: insights into its protective effect against cardiovascular diseases. Proc Natl Acad Sci USA, 2006; 103:2126-2131
19. Matz CE, Jonas A: Micellar complexes of human apolipoprotein A-I with phosphatidylcholines and cholesterol prepared from cholate-lipid dispersions. J Biol Chem, 1982; 257:4535-4540
20. Cho KH, Park SH, Han JM, Kim HC, Choi YK, Choi I: ApoA-I mutants V156K and R173C promote anti- inflammatory function and antioxidant activities. Eur J Clin Invest, 2006; 36:875-882
21. Esterbauer H, Striegl G, Puhl H, Rotheneder M: Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun, 1989; 6:67-75
22. Blois MS: Antioxidant determinations by the use of a stable free radical. Nature, 1958; 181:1199-2000
23. Huang Z, Wang C, Wei L, Wang J, Fan Y, Wang L, Wang Y, Chen T: Resveratrol inhibits EMMPRIN expression via P38 and ERK1/2 pathways in PMA-induced THP-1 cells. Biochem Biophys Res Commun, 2008; 374:517-521
24. Walsh MT, Atkinson D: Reassembly of low-density lipoproteins. Methods Enzymol, 1986; 128:582-608
25. Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA: Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis, 1987; 68:231-240
26. Gulledge AA, McShea C, Schwartz T, Koch G, Lord ST: Effects of hyperfibrinogenemia on vasculature of C57BL/6 mice with and without atherogenic diet. Arterioscler Thromb Vasc Biol, 2003; 23:130-135
27. Eckerson HW, Wyte CM, La Du BN: The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet, 1983; 35:1126-1138
28. Benzie IF, Strain JJ: The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem, 1996; 239:70-76
29. Markwell MA, Haas SM, Bieber LL, Tolbert NE: A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem, 1978; 87:206-210
30. Sakai M, Miyazaki A, Hakamata H, Suginohara Y, Sakamoto YI, Morikawa W, Kobori S, Schichiri M, Horiuchi S: Reconstituted high density lipoprotein reduces the capacity of oxidatively modified low density lipoprotein to accumulate cholesteryl esters in mouse peritoneal macrophages. Atherosclerosis, 1996; 119:191-202
31. Glomset JA: The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res, 1968; 9:155-167
32. Marchesi M, Booth EA, Davis T, Bisgaier CL, Lucchesi BR: Apolipoprotein A-I Milano and 1-Palmitoyl-2-oleoyl phosphatidylcholine complex (ETC-216) protects the in vivo rabbit heart from regional ischemia-reperfusion injury. J Pharmacol Exp Ther, 2004; 311:1023-1031
33. Forte TM, Subbanagounder G, Berliner JA, Blanche PJ, Clermont AO, Jia Z, Oda MN, Krauss RM, Bielicki JK: Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice. J Lipid Res, 2002; 43:477-485
34. Negre-Salvayre A, Dousset N, Ferretti G, Bacchetti T, Curatola G, Salvayre T: Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells. Free Radical Biology & Medicine, 2006; 41:1031-1040
35. Shah PK, Yano J, Reyes O, Chyu KY, Kaul S, Bisgaier CL, Drake S, Cercek B: High-dose recombinant apolipoprotein A-I milano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization. Circulation, 2001; 103:3047-3050
36. Durbin DM, Jonas A: The effect of apolipoprotein A-II on the structure and function of apolipoprotein A-I in a homogeneous reconstituted high density lipoprotein particle. J Biol Chem, 1997; 272:31333-31339
37. Cho KH, Park SH, Park JE, Kim YO, Choi I, Kim JJ, Kim JR: The function, composition, and particle size of high-density lipoprotein were severely impaired in an oliguric phase of hemorrhagic fever with renal syndrome patients. Clin Biochem, 2008; 41:56-64
38. McDonald MC, Dhadly P, Cockerill GW, Cuzzocrea S, Mota-Filipe H, Hinds CJ, Miller NE, Thiemermann C: Reconstituted high-density lipoprotein attenuates organ injury and adhesion molecule expression in a rodent model of endotoxic shock. Shock, 2003; 20:551-557
39. McBride PE: Triglycerides and risk for coronary heart disease. J Am Med Assoc, 2007; 298:336-338
40. Libby P: Fat fuels the flame: triglyceride-rich lipoproteins and arterial inflammation. Circ Res, 2007; 100:299-301